Optimi

Optimi is a commercial-stage pharmaceutical company manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. $OPTH

[Optimi @Optimi_Health]

A recent executive order aims to accelerate research into psychedelic therapies, potentially helping the U.S. catch up with markets like Australia which became the first country to allow authorized psychiatrists to prescribe #MDMA & #psilocybin. https://t.co/4yofhRoP2H via @CNBC

[Optimi @Optimi_Health]

Optimi’s 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United States and Europe. For details: https://t.co/ri6MnvglJn $OPTH

[Optimi @Optimi_Health]

Dane Stevens, CEO of Optimi comments on the expansion of psychedelic-assisted therapy access under the updated authorised prescriber framework in Australia. For more info: https://t.co/sOBJr3ZnkT $OPTH

[Optimi @Optimi_Health]

"Optimi is one of the only companies to take naturally derived psilocybin from biomass to a finished drug product, entirely under one roof and on our own licence.” - Dane Stevens on $OPTH's completed GMP production run of its 5mg psilocybin drug product. https://t.co/ri6MnvglJn

[Optimi @Optimi_Health]

Optimi announced the completion of a GMP production run of its 5mg psilocybin finished drug product. The finished psilocybin capsules use the same formulation already prescribed to patients in Australia for treatment-resistant depression. Learn more: https://t.co/xFtwWnbM49 $OPTH

[Optimi @Optimi_Health]

The recent updated TGA recommendations broaden therapist eligibility, accept a wider range of treatment settings, and reinforce Australia's position as the world's leading commercial market for prescribed psilocybin and MDMA. More info: https://t.co/sOBJr3ZnkT $OPTH

[Optimi @Optimi_Health]

Under the AP scheme, psychiatrists may prescribe Optimi’s #MDMA for PTSD & #psilocybin for treatment-resistant depression, making Australia the first country in the world to recognise & regulate both substances as medicines for these indications. https://t.co/sOBJr3ZnkT $OPTH

[Optimi @Optimi_Health]

Optimi has acknowledged the final recommendations published by Australia's Therapeutic Goods Administration (TGA) following its targeted consultation on the Authorised Prescriber (AP) scheme for psilocybin and MDMA. Learn more: https://t.co/J80HpThPFe $OPTH

[Optimi @Optimi_Health]

A portion of Optimi's newly completed extract has been earmarked to support upcoming clinical research programs in Europe, where the Company is expected to supply GMP-grade finished material into sponsor-led studies. https://t.co/TkPCXy40iv $OPTH

[Optimi @Optimi_Health]

Optimi has completed a production run of naturally derived psilocybin extract measuring approximately 6% psilocybin content, the highest-purity botanical extract produced by the Company to date. https://t.co/TkPCXy40iv $OPTH

[Optimi @Optimi_Health]

Optimi has announced the pricing of its underwritten public offering in connection with the uplisting of its common shares to the Nasdaq Capital Market. The shares are expected to begin trading on the Nasdaq Capital Market on May 20 under the symbol $OPTH. https://t.co/nCAmatGPrP

[Optimi @Optimi_Health]

Reuters: Trump's psychedelic EO has investors calling — $OPTI CEO Dane Stevens confirmed his company fielded calls almost immediately after the order dropped. $OPTHF manufactures GMP-certified pharmaceutical psilocybin & MDMA for regulated markets today.

https://t.co/orn2CcYYP4

[Optimi @Optimi_Health]

Analysts say GMP-certified psilocybin manufacturing is one of the sector's biggest barriers to entry. $OPTI has already cleared that bar; Health Canada-licensed, GMP-certified, actively supplying regulated markets today.

https://t.co/VVgEMaDoYE

#Psilocybin #GMP $OPTHF

[Optimi @Optimi_Health]

Following a White House Executive Order, the FDA this week issued national priority vouchers to fast-track psilocybin for treatment-resistant depression & major depressive disorder.

Article: https://t.co/pF0tSl8php

#Psilocybin #PTSD #Depression $OPTI $OPTHF

[Optimi @Optimi_Health]

970 million people worldwide live with a mental health disorder — yet fewer than 20% receive evidence-based treatment. The WHO calls it "a silent crisis hidden in plain sight."

https://t.co/UvEwKqmKHe

#MentalHealth #Psilocybin #MDMA $OPTI $OPTHF

[Optimi @Optimi_Health]

Optimi Health Files LIFE Offering Document in Connection with NASDAQ Listing.

Click here for details: https://t.co/kOtE86jYFk

#Optimi #LIFE #Nasdaq #Listing $OPTI $OPTHF

[Optimi @Optimi_Health]

Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products.

Click here to learn more: https://t.co/DRsYC1bycO

#OptimiHealth #Psychedelic $OPTI $OPTHF

[Optimi @Optimi_Health]

Australia's largest private insurer already covers psilocybin for treatment-resistant depression. Pharmaceutical-grade GMP supply will be essential. $OPTI manufactures Health Canada-licensed psilocybin & MDMA for regulated markets.

https://t.co/yQjh3uT8Ls

#Psilocybin $OPTHF

[Optimi @Optimi_Health]

The U.S. Dept. of Veterans Affairs has launched its first VA-funded study on MDMA-assisted therapy for PTSD & alcohol use disorder. As demand for pharmaceutical-grade supply grows, $OPTI manufactures GMP-certified MDMA & psilocybin.

https://t.co/aTpljNzYA4

#MDMA #PTSD $OPTHF

[Optimi @Optimi_Health]

Clinical evidence for MDMA-assisted therapy for PTSD continues to grow — and with it, global demand for pharmaceutical-grade supply.

https://t.co/WoVxva6OQL

#MDMA #PTSD #PsychedelicTherapy #MentalHealth #SmallCap $OPTI $OPTHF